Jiangsu Nhwa Pharmaceutical Co., Ltd.

Form 483 issued September 1, 2023 · Xuzhou, China

Inspection
Aug 28 – Sep 1, 2023
Observations
3
Pages
3
FEI number
3005619485

In short: On September 1, 2023, FDA issued a Form 483 with 3 observations to Jiangsu Nhwa Pharmaceutical Co., Ltd. in Xuzhou, Jiangsu (FEI 3005619485) after an inspection that ran Aug 28 – Sep 1, 2023. The investigator was Ers Alan P. Kurtaberg. Most observations concern quality system and materials; the most-cited regulation is 21 CFR 211.22 (responsibilities of quality control unit).

At a glance

2 of 3 observations on this 483 concern quality system.

Quality system2
Materials1

What FDA observed

Preview: the opening words of each observation

Dashed: section inferred by FDA Intel and checked against the regulation text

  1. 01

    Complaint investigation is…

  2. 02

    Written procedure is not followed to…

  3. 03

    Raw materials and APIs are not always…

The full 483

Plus the full detail behind each one, exactly as FDA wrote it.

Get the full 483

This inspection in context

Questions about this 483

What did FDA find at Jiangsu Nhwa Pharmaceutical Co., Ltd.?

FDA listed 3 observations on this Form 483, mostly about quality system and materials. The most-cited regulation is 21 CFR 211.22 (responsibilities of quality control unit). The opening words of each observation are shown on this page.

Who inspected Jiangsu Nhwa Pharmaceutical Co., Ltd.?

Ers Alan P. Kurtaberg is named on this Form 483, for the inspection of Aug 28 – Sep 1, 2023. Each investigator has a profile showing what they cite most.

When was Jiangsu Nhwa Pharmaceutical Co., Ltd. inspected by FDA?

The inspection ran Aug 28 – Sep 1, 2023, and the Form 483 is dated September 1, 2023.

How do I get the full Form 483 for Jiangsu Nhwa Pharmaceutical Co., Ltd.?

Download the original PDF from FDA Intel for $99, with no subscription. Your first Form 483 or letter is on us. You also get an invoice PDF with the order.

$99Get it free